DE69632141D1 - Lebend-impfstoffe gegen gram-negative pathogene, die heterologe o-antigene exprimieren - Google Patents
Lebend-impfstoffe gegen gram-negative pathogene, die heterologe o-antigene exprimierenInfo
- Publication number
- DE69632141D1 DE69632141D1 DE69632141T DE69632141T DE69632141D1 DE 69632141 D1 DE69632141 D1 DE 69632141D1 DE 69632141 T DE69632141 T DE 69632141T DE 69632141 T DE69632141 T DE 69632141T DE 69632141 D1 DE69632141 D1 DE 69632141D1
- Authority
- DE
- Germany
- Prior art keywords
- heterologous
- negative
- strains
- antigens
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- AAXCQFOXUJMCCW-PETQGJDISA-N LPS core Chemical compound O([C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]([C@@H](CO[C@]2(O[C@@H]([C@@H](OC3[C@H]([C@@H](OC4[C@H]([C@@H](OC5[C@@H]([C@@H](O[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)OC6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)O)O5)O)[C@H](O)[C@@H]([C@@H](O)COC5[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O5)O)O4)O)[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)O3)O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](O[C@]4(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C4)[C@@H](O)CO)C(O)=O)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)O1)OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C[C@H]1O[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1O AAXCQFOXUJMCCW-PETQGJDISA-N 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 244000000021 enteric pathogen Species 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 244000000058 gram-negative pathogen Species 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95116208 | 1995-10-13 | ||
| EP95116208 | 1995-10-13 | ||
| PCT/EP1996/004334 WO1997014782A1 (en) | 1995-10-13 | 1996-10-04 | Live vaccines against gram-negative pathogens, expressing heterologous o-antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69632141D1 true DE69632141D1 (de) | 2004-05-13 |
| DE69632141T2 DE69632141T2 (de) | 2005-03-31 |
Family
ID=8219717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69632141T Expired - Lifetime DE69632141T2 (de) | 1995-10-13 | 1996-10-04 | Lebendimpfstoff tragende stämme zur starken expression von heterologen o-antigenen gram-negativer pathogene und derivaten hiervon zum gebrauch als lebend-impfstoffe |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6613321B1 (de) |
| EP (1) | EP0854914B1 (de) |
| JP (1) | JP4189031B2 (de) |
| KR (1) | KR100451104B1 (de) |
| AT (1) | ATE263832T1 (de) |
| AU (1) | AU724002B2 (de) |
| CA (1) | CA2232563C (de) |
| DE (1) | DE69632141T2 (de) |
| DK (1) | DK0854914T3 (de) |
| ES (1) | ES2218602T3 (de) |
| GR (1) | GR950300072T1 (de) |
| MX (1) | MX9802881A (de) |
| PT (1) | PT854914E (de) |
| WO (1) | WO1997014782A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399074B1 (en) | 1998-07-24 | 2002-06-04 | Megan Health, Inc. | Live attenuated salmonella vaccines to control avian pathogens |
| US20030068324A1 (en) * | 2001-04-06 | 2003-04-10 | Jean-Michel Fournier | Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid |
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US10806778B2 (en) * | 2019-01-30 | 2020-10-20 | Prokarium Limited | Modified strain of Salmonella enterica Typhi |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU589114B2 (en) * | 1984-02-01 | 1989-10-05 | Enterovax Limited | Genetically engineered bacteria useful as a vaccine |
| US5110588A (en) * | 1986-08-19 | 1992-05-05 | Enterovax Limited | Composite salmonella E. coli, Vibrio cholerae vaccine strains |
| DE69221120T2 (de) * | 1992-04-10 | 1998-02-26 | Schweiz Serum & Impfinst | Rekombinanter lebender Impfstoff gegen Gram-negative enterische Pathogene |
| DE4221840A1 (de) * | 1992-07-03 | 1994-01-05 | Biotechnolog Forschung Gmbh | Bivalente Lebendvakazine gegen bakterielle Darmpathogene, Herstellungsverfahren sowie Plasmide und Stämme als Ausgangsmaterial |
-
1996
- 1996-01-31 GR GR950300072T patent/GR950300072T1/el unknown
- 1996-10-04 JP JP51547097A patent/JP4189031B2/ja not_active Expired - Lifetime
- 1996-10-04 DK DK96934548T patent/DK0854914T3/da active
- 1996-10-04 PT PT96934548T patent/PT854914E/pt unknown
- 1996-10-04 ES ES96934548T patent/ES2218602T3/es not_active Expired - Lifetime
- 1996-10-04 AT AT96934548T patent/ATE263832T1/de active
- 1996-10-04 KR KR10-1998-0702715A patent/KR100451104B1/ko not_active IP Right Cessation
- 1996-10-04 DE DE69632141T patent/DE69632141T2/de not_active Expired - Lifetime
- 1996-10-04 CA CA2232563A patent/CA2232563C/en not_active Expired - Fee Related
- 1996-10-04 US US09/051,536 patent/US6613321B1/en not_active Expired - Lifetime
- 1996-10-04 AU AU72859/96A patent/AU724002B2/en not_active Ceased
- 1996-10-04 WO PCT/EP1996/004334 patent/WO1997014782A1/en active IP Right Grant
- 1996-10-04 EP EP96934548A patent/EP0854914B1/de not_active Expired - Lifetime
-
1998
- 1998-04-13 MX MX9802881A patent/MX9802881A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| DK0854914T3 (da) | 2004-07-26 |
| WO1997014782A1 (en) | 1997-04-24 |
| JP4189031B2 (ja) | 2008-12-03 |
| CA2232563A1 (en) | 1997-04-24 |
| EP0854914A1 (de) | 1998-07-29 |
| CA2232563C (en) | 2011-12-06 |
| PT854914E (pt) | 2004-08-31 |
| EP0854914B1 (de) | 2004-04-07 |
| MX9802881A (es) | 1998-11-30 |
| ES2218602T3 (es) | 2004-11-16 |
| GR950300072T1 (en) | 1996-01-31 |
| US6613321B1 (en) | 2003-09-02 |
| JP2000506368A (ja) | 2000-05-30 |
| AU724002B2 (en) | 2000-09-07 |
| DE69632141T2 (de) | 2005-03-31 |
| AU7285996A (en) | 1997-05-07 |
| ATE263832T1 (de) | 2004-04-15 |
| KR100451104B1 (ko) | 2005-06-13 |
| KR19990064228A (ko) | 1999-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69632141D1 (de) | Lebend-impfstoffe gegen gram-negative pathogene, die heterologe o-antigene exprimieren | |
| Mancini et al. | OMV vaccines and the role of TLR agonists in immune response | |
| DE69806408T2 (de) | Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten | |
| HUT65496A (en) | Live vaccines | |
| ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
| DE69027313D1 (de) | Impfstoffe enthaltende avirulente phop-type mikroorganismen | |
| EP2141227A3 (de) | Hyperblebbing" bakterielle Stämme und ihre Verwendung zur Herstellung von Impfstoffen | |
| CY1107950T1 (el) | Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι | |
| MX9703017A (es) | Inmunizacion oral con plantas transgenicas. | |
| DK1181373T3 (da) | Delta-6-acetylenase og delta-6-desaturase ud fra Ceratodon purpureus | |
| Wang et al. | Optimization of antitumor immunotherapy mediated by type III secretion system-based live attenuated bacterial vectors | |
| ATE413888T1 (de) | Salmonella vakzine | |
| HUP9701586A2 (hu) | Javított inaktivált vakcinák | |
| Sousa | Pathogenicity mechanisms of prokaryotic cells: an evolutionary view | |
| DE69333751D1 (de) | Nicht-verbreitendes lebendes herpesvirusvakzin | |
| AR039846A1 (es) | Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo | |
| MX2019010015A (es) | Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar. | |
| GB2331521A (en) | Vaccine preparations | |
| Maddux et al. | Evaluation of recombinant attenuated Salmonella vaccine strains for broad protection against extraintestinal pathogenic Escherichia coli | |
| CU22835A3 (es) | Cepas portadoras de vacunas vivas útiles para la expresión a alto nivel de o-antígenos heterólogos de patógenos gram-negativos y derivados de los mismos para usarse como vacunas vivas | |
| Jiao et al. | The enhanced immune responses induced by Salmonella enteritidis ghosts loaded with Neisseria gonorrhoeae porB against Salmonella in mice | |
| AU1853995A (en) | Vaccine compositions | |
| Kamble et al. | Microbial Vesicles: From Ecosystem to Diseases | |
| NO20063020L (no) | Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: BERNA BIOTECH AG, BERN, CH |
|
| 8364 | No opposition during term of opposition |